Latest / Stand In The Circle / Stand in the Circle: Psychedelics, Anxiety & IBS with Dr. Franklin King
Transcript
- speaker-0: We were hoping to find that on the heels of psilocybin that people's sleep would improve, but actually sleep went down, and it did make me wonder if we're seeing this physiological effect of the blast that psychedelics can often give to people. speaker-1: Why do we have this model where we think the work finishes after a couple of weeks? From what I'm seeing, it really is multiple years. speaker-0: Participants tell us in the study. Wow, I just I had no idea how much work that was going to be. speaker-1: I guess as the models that get licensed will probably be quite medical. The more I'm interested in d tools that can be wraparound tools that people can find themselves speaker-0: I've done a lot of holotropic breath work and of course, you know, the nice thing about breath work is if you really do need to slow things down, you can. speaker-1: Welcome to Stand in the Circle with me, Dr. Rosalind Watts. I'm a clinical psychologist, researcher, and founder of Acer Integration. This podcast is about how we get connected in a culture that pulls us apart. We talk about the hardest experiences of being human and the circles of care we have needed, couldn't find, and are searching for now, with stories from people who've lived it and researchers and practitioners. Healing in community is the older way. The work of our time is to rebuild our connectedness to ourselves, to each other, and to the living world. So welcome Franklin King to this podcast, Stand in the Circle. This month we are talking about anxiety, IBS and anxiety. Franklin is a psychiatrist and a researcher, and he is the director of training and education at the Massachusetts General Hospital Center for Neuroscience of Psychedelics, and he's been involved in research looking at psilocybin for IBS, which is very relevant for us because in our last episode we spoke to one of the ASA community members who talked about how. Psilocybin was a huge part of this journey where she now considers herself not to suffer from it anymore, which is really a life-changing and amazing thing for her to realise. You know, it's it's been decades of suffering. ⁓ and Franklin is also doing research looking at MDMA and chronic pain and fibromyalgia, things that people in our community also contend with. So, Franklin, thank you for your amazing work. Please tell us a bit about your journey to doing the work that you're doing now. How how did you get here? speaker-0: Okay. ⁓ well first thanks for having me. And yeah, I I I think the psilocybin for IBS study was really amazing. We just finished kind of the main part of it not too long ago. We're writing up the manuscript. And then we have long term follow up that we're gonna be collecting with qualitative interviews of people up to about a year after they finish the study. So hopefully we'll you know the qualitative stuff is so rich. As as you know. ⁓ yeah, so there's that study. I'm happy to talk a little bit more about that. There's the fibromyalgia study. So that's being run ⁓ by a friend and colleague Vitali Napadao. He's ⁓ professor, ⁓ does pain research and ⁓ pain neuroimaging. So that study we're gonna look at ⁓ what Vitali studies in particular is Hyperscan. So he scans two people simultaneously. And he's done a lot of work with ⁓ change in pain in response ⁓ to an intervention such as acupuncture, and then he'll do serial scans of the of the treater, for example, the acupuncturist and the patient, and looking at measures of brain-to-brain concordance and how changes in that or how like measures of brain-to-brain concordance can predict or correlate with treatment response and reduction in pain. ⁓ so You know, MDMA seems to have something to do with how people get along with each other. So we anticipate that it will lead to changes and maybe we'll be able to see how that predicts reduction in pain. We haven't ⁓ enrolled ⁓ we haven't dosed anybody yet in that study, but we're like actively starting out. So that's kind of those two things. I can talk about some other a couple other studies that we have sort of like just getting going. ⁓ That are probably about a year away, not even with IRB ⁓ approval yet, but sort of just beginning the regulatory steps. We're going to be doing some ⁓ work with our veterans clinic, Home Base. It's part of Mass General, but it's its own site. And we're gonna be doing a group study. I'm gonna be looking at group MDMA embedded in a residential program that's that already exists there to basically see, you know, can we customize this program, can we change it? Can we just add MDMA into it with with you know the usual preparation and integration? And then we're going to be doing another hyperscan study with couples. So with veterans with PTSD and their partners. And so I think that that's going to be ⁓ particularly interesting. ⁓ and we're also doing a project with fireside and I'll stop after this, but we're ⁓ we have a ketamine infusion clinic at MGH and with partnering with them and with Fireside Project to offer fireside psychedelic coaches to patients who are already getting ketamine. So essentially you have kind of ketamine and more of the infusion model and seeing if you can offer three months of psychedelic informed coaching delivered over Zoom, you know, rather than sort of constructing the perfect ketamine assisted psychotherapy, it's more, you know, this is an existing system. Can we kind of graft on something that's psychedelically informed? Kind of like lightweight therapy esque intervention, see if it works. And so we're getting some pretty some positive responses at least from study participants so far. We're about halfway done with that. So I guess I'll stop there. I just talk speaker-1: This is obviously incredible work, groundbreaking stuff. How how did you come to work in psychedelics? 'Cause it's, you know, I suppose it's becoming more mainstream now, but it's still n you know, not the typical route for a psychiatrist. So what was it about psychedelics that called to you? speaker-0: So, I mean, I've been interested in psychedelics, you know, going back to being a much younger person. Also did not think of them as like when I first heard about this in medical school and started doing some some research. ⁓ the story is I we were getting an anesthesia lecture. Anesthesiologists then started talking about migraine treatments, talked about Five H T two way agonists methyl surgite and other stuff that used to be used for migraines and how that was the same mechanism as psychedelics. So I go to PubMed, start looking it up, find Matt Johnson's paper. I'm like, this is this is what people are doing with psychedelics. This does not really seem like the place that I would expect psychedelics to be most helpful, but kind of kept kept an eye on the research as I went into residency. And then sort of through a ⁓ a bunch of failed attempts. ⁓ of you know, getting involved or or getting connected with people doing research when I was an intern and then serendipitously kind of finding myself getting MAPS training in twenty sixteen. And that was really kind of the moment for me where I was like, all right, like I I guess this could be really helpful, you know, for patients in a psychiatric setting. I I really was not I I was I just didn't really see it. ⁓ until seeing until participating in the maps training, you know, which as many people listening probably know has a lot of videos. It's lots of videos, you know, of preparation, MDMA sessions, integration sessions. It's very intense. You know, you're sort of on residential campus is the way they used to do it. You know, so you're with like thirty trainees for twenty four seven for a week, you know, watching very, very, very intense processing of very, very, very intense trauma. And I think just kind of seeing how it actually worked was really what was, you know, sort of this I don't know, I guess a breakthrough moment for me. After that I was sold. It was really the actually the maps training that made me like really realize that this this there's quite something here. So I've been trying to get stuff going ever since and things are slowly starting to pick up. So yeah. speaker-1: That's really lovely to hear. What was it about the the training that spoke to you so much? speaker-0: I think it was a lot of things. ⁓ You know, and I and I certainly don't just to be you know very clear, I certainly don't think that psychedelics are a panacea. I don't think they're going to work for everybody. I know like I know that they're not going to work for everybody. And so I don't mean to imply, you know, just being like blown away in in in that particular way. That being said, there's just there's no arguing with the fact that, you know, if you can get one person with PTSD as significant as some of the folks in the early studies ⁓ that you know were kind enough to allow themselves to to be videoed and and their cases shared as part of training, you know, this is an extraordinary signal. Right. I mean, if you work with people suffering with, you know, very severe psychiatric symptoms, you know, that you know, people that are, you know, barely functional, just like incredibly deep and chronic impacts on their lives. And being able to see how they are before and after, just in the way they speak, in the way they they hold themselves, the impacts that it had, you know, in one person on their relationship with their wife. ⁓ but the other part was, you know, actually seeing how this was working. Like really being able to see ⁓ you know, the the the videos of the MDMA sessions and the way that people Who had severe PTSD were able to, you know, the one particular person was able to just really ⁓ incredibly lucidly go right into the particular traumatic event. And just seeing this person be able to kind of process it, ⁓ you know, without any avoidance and yet also without sort of spiraling into an emotional response, which would have previously been impossible, was really impressive. So I think it it's not just The symptom reduction, it's not just the fact that psychedelics work, it's how they work, which I find very appealing. And and I think it's something that the field of psychiatry has come very far away from. Right. I mean, we're we're very interested in kind of, you know, the box of symptoms going from, you know, X to Z, but you know, the the actual act of how that happens and the human participation in that process as opposed to simply just responding to kind of an external intervention, be it drugs or ECT, you know, we've kind of really come a long way from that. So speaker-1: And it's lovely because that was ten years ago now, I think. Did you say you did it in two thousand and sixteen or speaker-0: Yeah, it was act yeah, it was right around this time of year. It was ⁓ early October twenty sixteen. Yeah. speaker-1: And you remember it with such clarity, you can still remember the videos. It obviously really had such a profound impact on you, which is yeah, that's it's quite moving to hear. so I would like to think a bit about the IBS study, because as I mentioned before, we had like our previous episode of this podcast was focusing on both how psychedelics can treat anxiety and how psychedelics can also trigger anxiety. So in the last episode we had two members of our Acer community We had Indira speaking about, as I mentioned before, a psilocybin kind of ongoing psilocybin journey really helped her with her IBS enormously so that she felt that she could communicate with her gut and that it completely changed. And then we also spoke to Sin, who is also in our community, and she talked about taking part in a five MEO DMT study and it was for depression, and it helped with her depression. But after the study, she's had quite serious ongoing anxiety, panic attacks and just ongoing kind of embodied experiences of physiological anxiety. So I'm really interested in this idea of how psychedelics can both, you know, because for a lot of us when we think about psychedelics anyway, and for people that have had a psychedelic experience, one of the first things that will come to mind is anxiety, the fear of the experience there, you know, the anxiety before it. Even people that are seasoned psychedelic users will say that they feel anxiety before an experience. It's a very intense thing to do. So I I'm very interested in this idea of psychedelics and anxiety and how they can help it and also trigger it. So yeah, riff on any part of that that you would like to. And I'm really interested in what you found with the IBS ⁓ study as well. speaker-0: So yeah, I think well interestingly we have the chair emeritus of the electrophysiology department, you know, the guy that basically set up the huge now subdivision of cardiology at MGH like decades ago. Still practicing, very interested in psychedelics and for many of the studies has Provided Fitbit like devices that people have worn and people wore in the IBS study. And we were there, I'm trying to remember. I'd have to look it up and it's it's the this manuscript's already been submitted. ⁓ hopefully it will be accepted soon. But we were hoping to find that you know on the heels of psilocybin that people's Sleep would improve, ⁓ you know, it looks at sleep, it looks at ⁓ you know how much people are moving during sleep, it looks at heart rate variability, it looks at average heart rate. So we would have thought that average heart rate maybe went down a little bit, that there would be an increase in heart rate variability, that there would be an increase in sleep, but actually sleep went down like everything moved in the wrong direction very, very slightly. ⁓ and but there there were these changes that were kind of in the opposite direction. Now we only looked, I think through maybe one or two weeks after the second psilocybin session. We did two doses in this study. So, you know, first of all, this is a 14 participant study. So, you know, we have no control either. So this is, you know, we have to be temper everything that we find here as being revelatory of something that would be replicated in a larger trial. But it did make me wonder if perhaps, you know, most of The our trial participants did not have prior psychedelic experience. And it did make me wonder if there is this sort of, you know, there's we're seeing this sort of physiological effect of the blast that psychedelics can often give to people. And I do think, you know, I mean, there's different words of describing it. Ontological shock has been one term that's okay, I guess. But I mean, psychedelics really can. ring someone's bell pretty hard. And sometimes that can be good and sometimes it can be not so good. I I think the kind of psychedelic attitude and model and kind of psychedelic therapy way of doing things generally has been, you know, just kind of like leaning into whatever, you know, is being felt, whether it's you know negative or positive. And I I'm not so sure that that's always the case. I'm also not so sure that we know when when to sort of stick with that and when to say, okay, like like like something beyond just something that's therapeutic is happening here. ⁓ I I'm very into history. I was a history major in college and I've been on this like multi month history project right now of like basically going through what hopefully will eventually be, you know, most every paper that was written in the nineteen fifties and early nineteen sixties before things spun out of control. And it's interesting because that's a period of time, I mean, particularly up until like 1962, 63, before there was any controversy associated with psychedelics. And, you know, so they're sort of untainted with this kind of all the public ideas that people have now with them. And you know, people going right back to the beginning were having prolonged negative reactions to psychedelics. And so it it it's it's not that this is a new discovery. You know, the question is I think, you know, what what is that? And then what does one do about it? Like would another psychedelic session be useful? A lot of ⁓ teams, like Ronald Sanderson in ⁓ in the UK, but you know, they would have like, you know, the program with multiple sessions of L S D over many months. you know, would that be helpful? Are there cases where, you know, th you want to try something else? Are there cases where pharmacological intervention is needed? I think yes. ⁓ but I think, you know, these are really important questions for the field and we don't we don't have a lot of guidance, we don't have a lot of evidence to to know what to do in those particular situations. speaker-1: Mm. It's so interesting what you say about ⁓ this model that we have at the moment, which is kind of, you know, accept that whatever is presenting itself is all part of the unfolding and be with it. But that's really interesting that you're sometimes wondering whether actually Yeah. I guess it's hard to know how to respond in circumstances like that because you really don't want to be too directive when someone's in their experience. So yeah, have you have you found any ways through or have you you know do you get to be in the sessions as well? Do you get to take part in the in the actual sessions? Great. Did you play around with that ever? Like I mean, play around sounds very flippant. When someone's having an experience like that, it doesn't it feels extremely serious and and and heavy to not know how to help them. Did you find ways that that were different to that model of just we accept whatever is showing up as part of your healing process? speaker-0: Yes. But I have that that's kind of my my attitude in general. So I think I don't know, I mean this is a a big topic, but I I think you kind of you have a lot of different there are a lot of worlds within psychiatry. And there are a lot of treatment models. And I don't think we appreciate the extent to which both the clinician and the patient involved in any particular interaction in terms of what their sort of clinical and therapeutic orientation, how much impact that actually has on outcomes. So I'm not saying that there's there's nothing objective, but you know, if somebody absolutely believes that. They are exquisitely sensitive to psychiatric medications, that is absolutely going to predict that they're going to have reactions to psychiatric medications. I'm not saying that that, you know, for people that are, you know, have strong opinions about psychoids, I'm not saying that like all negative reactions are, you know, psychosomatic or or imagined, but that what the the way that a patient, I think, conceives of how they're going to therapeutically respond to something shapes how things To a certain extent, it will play out in the treatment courts, as does the way the clinician thinks about what's happening. And we really don't think about that very much because patients and clinicians, for the most part, kind of sort themselves into different treatment models. And so if you're somebody who really believes in working over several years on deep psychological issues and you have the means to do so, you're probably going to find your way to long-term dynamic therapy or psychoanalysis. And if you're a clinician who believes in that as a valuable process, That's the kind of work you're going to do. If you totally believe that, you know, that your symptoms are the product of something biologically based in the brain and that there's really no kind of personal engagement necessary in the recovery, I think you're going to find yourself probably more likely to feel totally okay with a 10-minute appointment with a psychopharmacologist, likewise for the clinician. And it's interesting because psychedelics are kind of pulling. For a mixture of multiple different worlds. You have this situation where there's kind of a A blinded reductionism as to what psychedelics actually do, where the kind of the media portrayal of them is simply that these are these incredible miracle cures where, you know, if you've been suffering for a long time, all you have to do is, you know, you know, maybe with a guide, but still all that one has to do is be given as a passive recipient psilocybin or LSD, and the symptoms are gonna go away. And I think that that sort of Culturally held, that's kind of the way that psychedelics are seen. It's starting to change. But it's not just the hype, it's the kind of conceptualization of how much work psychedelics actually are going to be. And I think that is unfortunately kind of advertising psychedelics in a way that is not setting people up for realistic expectations. And it's to a certain extent attracting people who are looking For something that actually is quite different than what psychedelic therapy, as I described a few moments ago, is all about. So that's not to say that like there are ⁓ objective responses that people can have, that people can't have long-standing anxiety from a single psychedelic experience that's really going need some management. But I also just wonder about how much someone's kind of expectations of what the treatment is going to be. You know, if you have somebody come in and had extensive experience, maybe with you know, like 10 day, 15 day silent meditation retreats over many years and can kind of tolerate that versus somebody who has, you know, only gone for biological models. I I I I just don't know. I think i like this would be very hard to study and it's really just gonna kind of come out over, you know, years and decades once we sort of get this into the light. But I I have found, you know, when I talk to both clinicians and the public about psychedelics, that really the hardest thing is kind of conveying like what this is all about. That doesn't mean that psychedelic assistive therapy ⁓ the way that I'm talking about is really the the final way that this is going to work. I think it probably is the best, but you know, you could call that an empirical question. But just the amount of time of kind of describing to people, this is really going to be a lot of work. And it it's not going to end the moment psilocybin is left to your system. And there could be some, you know, longer term shaking up after effects, which is why I mentioned, you know, there maybe there's some cardiological correlates with that that we're seeing in this these Fitbits. ⁓ And we had participants tell us this in the study, and we did a lot of preparation with them. And they still said, you know, like, wow, I just I had no idea how much work that was going to be. And I in no way say this to, you know, suggest that people who suffer after psychedelics are not doing the work. I'm not implying that. I just I think it's more this sort of like, what is it? Like we're all we talk about is psychedelics. We don't it's not even talking about the therapy. It's about like the role of the person and how much work this is going to be. And when I say work, if you don't, you know, have a history of Being a psychotherapist or a therapy patient, like people don't even know what you're talking about when you use that word, work. Yeah. speaker-1: Thank you for saying all of that. And yeah, it's interesting because Indira in our community, she talks about this journey that she went on being a very long, multiple, you know, multiple years journey where she had an experience and then it was too intense. And so she worked with breath work and worked with ⁓ hypnotherapy and and slowly, slowly got herself to the point where she could have another experience and then another one. But it was we're talking about, you know, you ⁓ you talk about work. She was working on this for years with a team of up people. She was in a community of many people who were therapists. ⁓ she was deeply, deeply engaged and actually started like working as a psychedelic integration coach herself because she became so deeply immersed in the work. And then the other ⁓ community member I mentioned, she came to us because the trial didn't give integration really, just a a very small amount. And so she came to us to do a year's worth of integration because of the same thing. It was like Why are we why do we have this model where where we think the work finishes like after a couple of weeks? It's it really from what I'm seeing, it really is multiple years. You know, it's we we we're working in units of years. Like how many years are people in our community? Many have been in for four years now, which is the long as long as we've been kind of going. But it is interesting, isn't it, as in the psychedelic therapy world, as we're seeing the models being developed, the ones that are being licensed, less and less therapy. And so it's going to fall more and more to fireside, as you say before, like community organizations like us, like Fireside, and I'm sure there'll be so many more that develop, which are stepping in to say, okay, you've left the clinic. Hello, we're here. We, you know, we welcome you to begin the work, which now might take months or years. And it's a real privilege to do that work when you have other people with you to do the work. But it it certainly feels like in our conceptualizations, we we kind of missed out that bit. And maybe that is bit unfair on participants sometimes because they don't realize, as you say, they don't have a conceptualization of it. But but it's interesting because you mentioned about Ronald Sanderson and these ⁓ psychiatrists that were working in the 50s and 60s. What was their model of kind of integration afterwards? How how did they or from any of these papers that you've been digging up, like how long did they think people should be working on this and what were the methods that they gave people for working on it? Was it psychotherapy? What did what did they do? speaker-0: It really d I mean, there was a there were a lot of different models. Like a lot of models. I mean, there was there were some people associated with Sandison, you like like Joyce Martin and and and some other folks that who you know did some pretty stuff that I think today would be considered by just about everybody as pretty weird. ⁓ I I won't get into it, but if you look them up too. You can you can you can look them up. But I I mean, there were there were a lot of different models. There was nothing that was completely standardized, but obviously, I mean, there were the sort of like the peak experience models of what became psychedelic assisted therapy as we practice it now. I mean, you know, even the sort of reduced pharmaceutical company models essentially are doing psychedelic assisted therapy. And then Sanderson was doing more psycholytic. He actually coined the term psycholytic. But, you know, they weren't necessarily giving very low doses of LSD. I mean, people were having often, you know, complete psychedelic experiences. And there were many sessions that were done with LSD over a very long period of time. You know, we're talking, you know, many weeks, months usually, often in a residential environment where people would go, you know, basically like living in a psychiatric institution for a long period of time. And getting multiple treatments with a lot of psychoanalytically informed therapy, which I think in Sandison's case was but was Jungian analysis. So he was looking at archetypes and animus and anima and and stuff like that that LSD was bringing up. But there wasn't there wasn't one model. Other people were doing ⁓ you know, more sort of Freudian psychoanalysis. Others, you know, started finding that, you know, none of the theories really matched and kind of coming up with their own. Theories, others were not really looking at it in any particular way and just offering a little bit of preparation and a little bit of processing afterwards. ⁓ One thing that I you might find quite interesting that I've come across in many papers is how common it was, particularly in these psycholytic models. Which again, I I had kind of gone into this project imagining psycholytic to be pretty consistently very low dose of LSD, like, you know, as much as like fifty micrograms, but not more, which is really not the case. But people were pretty frequently, many different clinics in Europe would give thorazine or another antipsychotic after a few hours of LSD, maybe after like five or six hours. And this was not Like I found no paper where there's a lot of discussion why, other than that they wanted to just send the person home and let them go to sleep. And I've read patient reports of their own experience, you know, not describing this as being a problem, which is funny because I think the kind of psychedelic attitude now is that, you know, that every component of the experience is valuable, including like the whole arc of, you know, coming out of it. And so it's just interesting that it seemed to be working just fine with people having about, you know, half the amount of time of an LSD experience at most. Dosing them with 50 milligrams of thorazine and then sending them on their way. And it was still therapeutic, which gave me a little pause. Because at first I read that and I was like, this is not kind of like, you know, dishonoring, you know, what, you know, the value of like a long LSD experience. But everybody bought into it. And perhaps that was actually the most impactful aspect of why it seems to have worked, more so than if you kind of tried this now when the You know, the people conducting such a study would probably have some misgivings about it. speaker-1: Wow, that's that's that's absolutely fascinating. It's got me wanting to like read all these papers now. What will you what will you be doing with all the papers that you're finding? Are you going to be yeah w what what's the plan? speaker-0: I'm trying to I I I have this completely out of control co-working project that's creating a database essentially of every paper. And then I I'm trying to build like an AI tool that will let me search all of the papers. So I've been acquiring all the papers ⁓ essentially from nineteen forty seven to nineteen sixty three. So my sort of the point where I lose interest is the year that Leary and Alpert were dismissed from Harvard. So I don't I don't know what I'm gonna actually do with it. Probably, you know, try to extract some information and maybe, you know, just write a few articles on areas of interest to me. But we'll see. speaker-1: Well and that makes me think about ⁓ the kind of current state of the research 'cause there's so much psychedelic research happening at universities all over the world now. I've completely lost track with everything that's happening. speaker-0: You can't keep up with it anymore. It's just yeah. Yeah. speaker-1: Do you in terms of in terms of anxiety though, because in the back in the day when I was kind of in the field as a clinician, it was very much focusing on depression and there was some work with PTSD and MDMA, but it was kind of depression and PTSD. And now there are so many other areas of research. With anxiety, yeah, like could do are you aware of a kind of I mean, it's totally fine if you're not. I I have no idea. Could you give us a kind of like broad lay of the land of like psychedelics and anxiety disorders? Where are we in twenty twenty six? speaker-0: Well, I mean I think if ⁓ some are skeptical about well, I shouldn't even mention any any companies just for the sake of it, but I've heard from some that there's skepticism that the FDA is going to approve psilocybin first. I don't I've no idea. I mean, I'm not involved in that in any way. But I do think it w it would certainly be quite kind of strange, I don't know if ironic would be the word, if LSD, you know, ended up being the drug that got FDA approval first. You know, if like if I mean MDMA got the rejection, maybe, you know, I know it's been resubmitted. I I there's no doubt that psilocybin, you know, eventually will be approved. But it would just be interesting if L S D kind of made it to the finish line first, after being, you know, the least probable one. But it is being researched for anxiety. It's it's interesting. For generalized anxiety disorder, of course. But I think that's kind of where all the attention is on anxiety. I'm not I don't know. I'm not I'm not actually aware of any other studies of of you know, pure anxiety disorders. I mean C D doesn't really fall into the category of anxiety disorders. ⁓ I don't know. Is somebody doing any research on panic disorder? Is d is that being done? ⁓ speaker-1: seen it and it's so interesting again to think about it because when I think about the experience of working on the psilocybin for depression trial there was so much panic in the participants because of the experience. So it's kind of when I imagine people with panic disorder having an experience that then could elicit, ⁓ I remember quite a few of our participants had kind of near panic attacks at the start. and for some people it was just, you know, and I can really relate to it because I've had some terrifying experience, you know, I can really relate to that feeling of like you really are kind of diving off the deep end. So I can see why somebody that is inclined to anxiety, ⁓ they're gonna find a psychedelic experience even more kind of intimidating. I wonder about ⁓ whether microdosing models will be brought in or more psycholytic models, this kind of therapy plus smaller doses, but but I haven't seen anyone looking at that. And I don't know whether from as a psychiatrist and a neuroscience expert, I don't know whether the mechanisms there would w whether that would actually make any sense to to look at microdosing. What do you think about microdosing overall? 'Cause I we have such varied opinions. All of my medical friends say, ⁓ it's placebo and then lots of people I know that microdose say, It's definitely not placebo. So yeah, where do where do you stand on microdosing? speaker-0: I don't know. I think it's I think for you know, I'm sure that for some it's placebo and it seems like, you know, for some people it's it really works. I mean that that's not a very scientific response. It's awfully hard to study microdosing, at least especially in the United States, 'cause there's so many there's so much monitoring and strictures. I mean, you can't send somebody home with, you know, a month's supply of ⁓ Psychedelic, even if it's a a microdose. ⁓ so I don't know. I mean, it's it's it's hard to not imagine that that for some more than others, there's probably a discrepancy among individuals of what you know 10 micrograms, 15 micrograms of LSD might do to someone's mood. And, you know, could that open up problem solving ability and introspection that could nevertheless, you know, just in the way that larger doses can do, could that, you know, lead to over time some breakthroughs and changes longer term in behavior? Because that's really what I mean, I I'm I'm just not as interested in microdosing only because I'm not interested in pharmaceutical models of care. I'm not saying they don't work. It just doesn't inspire me. but I could see, you know, maybe I mean if you can diminish, you know, negative affective states. You know, throughout the day. I mean certainly that allows more sort of mental space for, you know, someone's ongoing work to proceed, for them to, you know, make changes in their life that sustain further improvement. Yeah. I don't know. Yeah. speaker-1: One of the things that we focus on in our community is about connectedness, connectedness to nature, connectedness to others, connectedness to self. And I wonder about, you know, in a kind of post legalization world where whether it might be that, you know, there's a huge amount of work with people, like you say, using microdosing to enable them to connect to the things that they know they want to connect to, but at the like in their current lives it's too difficult whether they are just trapped in patterns that they can't break through. So they're stuck in they just feel stuck. They feel stuck in the life feels a bit like a prison and they can't really break out. And they know that they want to go and like hug a tree in a forest. But they also they wouldn't feel great doing it because they're feeling stressed and worried and they don't really want to go into the rain and find a tree. But if they were maybe supported by community and maybe by some kind of microdosing element that might allow them to just feel a bit more relaxed, let go, that maybe it would just be the doorway to engaging ac in activities that people know they should do, but don't really have somehow don't really have the openness for in their current state. So speaker-0: Yeah, right. I mean I I think we we often sort of think too much about symptom reduction as an a as an end rather than as a means to something. So if there's something that somebody, you know, sort of wishes they could do or they're they're or they're or they wish they wanted to do it, but they're blocked from anhedonia or lack of motivation because of depression, but you kind of remove that blockage and then that i it's not that like hugging the tree even is the outcome. It's not the end, but if doing that actually leads to a greater sense of fulfillment and reward that then actually, you know, is like a platform for further positive change. I mean I think that's really what what matters the most. I mean, absolutely, like like making people feel better, of course, is is a goal in healthcare. But if the only thing is sort of like a transient reduction in symptoms with no further speaker-1: Yeah. speaker-0: progress. I mean, that that is still something, but wouldn't it be nice if, you know, if it was leading to something more? And I think that's, you know, I mean, there's plenty of evidence that even conventional antidepressant therapy, you know, particularly when paired with psychotherapy, can lead to greater change, you know, than either alone. Right. speaker-1: Mm, yes. And it does slightly concern me that we saw that with antidepressants, how much more it powerful it is to combine. but yet we still I don't know if it if it's that we haven't really learned the lesson with psychedelics, because obviously there's less and less, the kind of therapy as the model develops, or whether it's just yeah, it's just gonna it it's going to come back and weave together these two important strands, but they're just kind of being held by different people. So I I have real hope that you know, th the the model of psychedelic usage that will be adopted by most people as it becomes truly mainstream will be one where ⁓ psychedelics are very much seen as something that can open the door and then the work begins, the community work, the work with, you know, whatever it is that's important with this ongoing process. But yeah, I don't really yeah, I don't really see the plan for that yet. I don't really It but it seems kind of obvious to me. Do you in the world that you occupy, ⁓ would you say that there's there tends to be a kind of sense of, you know, the the kind of pharmacological model of these are going to be licensed drugs, people are gonna have them in the clinic, a bit like they often do with ketamine, and then, you know, that's it. Or is there a sense of a real hunger for finding the ways to combine the drug with the Community support, therapeutic support, the work. speaker-0: Both. I think both. I mean there is certainly It's no secret. There's there's a lot of interest in the wrong stuff with psychedelics and Yeah, it it's it's hard to not worry about what that's gonna look like. On the other hand I have to temper that a little bit, knowing that, you know, when this first starts, it's like basically we are a culture, you know, on average, that has very little facility with you know what we're all this stuff that we're talking about. You know, principles of psychotherapy, psychedelic states. ⁓ and I I'd like to think that just because of the way psychedelics work, That, you know, as these treatments become available, that that people will kind of learn, similar to the way that people learned back in the fifties and sixties, that there really do need to be psychotherapeutic structures around these things. Probably there's going to be a lot of turbulence as this happens. I guess, you know, the the thing that worries me though is that these are going to be pharmaceuticals, that there's not going to be a change, at least in the United States. It it's not going to affect in any way. The Controlled Substances Act. It's not going affect in any way the legality or illegality of psilocybin, LSD, MDMA, you know, naturally or non-naturally occurring psychedelics. Those are not going to be rescheduled. The proprietary formulation is going to be rescheduled, which is which is one thing, and there's that's more of a political question, but it does bear on psychiatric outcomes, particularly because we have this. Curious process in the United States right now where states are beginning to create these state level programs that are not using FDA approved compounds. And yet the federal government is kind of allowing federalism to sort of do its thing. But, you know, I mean, technically, just like with cannabis shops, they could come in and, you know, raid these places anytime. As much as, you know, the the people that love to see the Oregon model. fail make a lot of noise about how expensive it is, which it is expensive. But I don't think that the costs of the Oregon psilocybin model, the raw costs, hold a candle to what psilocybin. I saw something yesterday on Twitter that, you know, looked at sort of one company's cost analysis and extrapolated that they're planning on 17 to 22,000 US dollars per dose of psilocybin. It's lot of money. Now, drugs are always expensive when they first come out. So that like like drugs are really expensive when they first come out. They're not that expensive, but they tend to be expensive. So it is possible, as egregious as that figure is, that over time costs will come down substantially. But the type of you know really being able to flexibly offer these treatments. in the way that you're describing, especially to be able to sort of calibrate dosing flexibly is gonna be impossible if the cost doesn't adjust itself over time. speaker-1: That's steep. How ⁓ how is the I mean, I suppose ⁓ rescheduling would be one way that that cost would dramatically decrease. ⁓ and that does actually make me sad for other reasons as well. It feels so strange to have so many people incarcerated for using the same substances that then a company can license by having a particular you it does I mean the kind of hypocrisy of it feels like really quite awful. But I guess speaker-0: Just incarceration. I mean, you know, there's not a lot of people that are incarcerated for psychedelics. I mean, ⁓ I I don't think anybody should be for any drug personally, but ⁓ you know, the the raw numbers of people incarcerated for psychedelics. But that's just you know, i i I don't I don't know how it is in the UK, but you know, we're pretty we're we're a pretty punitive country, you know, aside from the carceral state, there are plenty of people who get arrested for psychedelics. They don't go to jail for it. But You know, if you're eighteen and get arrested with mushrooms, you have to tell your college when you're applying to college on your college applications that you were arrested. You know, you have to do that when you apply for a job. So so there are a lot of things beyond just like who's in prison that, you know, follow people around for the rest of their lives. So I would just kind of a lot of people kind of don't don't think of that. At least in this country, you have to like really subject yourself to a criminal background check for almost anything now. Yeah. speaker-1: What are what are the other factors that might bring the cost down? Because that feels really heartbreaking that it would be so inaccessible, especially when, you know, it's like it just seems so crazy when a lot of these things go in the ground, you know. speaker-0: I read this on Twitter. I should I I I never even go on to it. I don't know why I went last night, but it was right before bed and I I saw this health economist ⁓ who came up with that figure. As I went to sleep, I was like, Man, I'm imagine if the government nationalized psychedelics. I'm not suggesting that, but I I do think I mean that would be one way if I mean if the government decided w I mean if the VA decided, for example, that it was going to create its own program. that was going to, you know, not be extraordinarily expensive. I mean we we could do this. If it it would be possible to do this. ⁓ you know the VA could do an Oregon model right now if if Congress authorized it. So you know, these are extreme pie in the sky ⁓ things. But speaker-1: It's good to think of the pie in the sky. would you you mentioned earlier the Oregon model being like seen as some as a failure. And I hadn't really heard that before. Can you say a little bit more about that perspective and what people that would say that would base that on? speaker-0: I d well I d I didn't ⁓ I think people There are a lot of people that have had kind of dim views of of the state level programs for various reasons. The main critique of the Oregon model is that it's too expensive. And I think the most I mean, this data is out there, and I couldn't tell you the specifics, but you know, the a a large proportion of people availing themselves of the Oregon program have been out of state people. You know, so there's sort of like a medical tourism element. Now that doesn't tell me that it that it it's been unsuccessful. I mean I I think it's clear ⁓ unfortunately right now, I don't know if they've made a decision yet. I know in the last like few weeks, Oregon, the state government was considering substantially increasing the licensing fees. From what I understand of the Oregon model, you know, one of the problems was that the you know the pro the cost of like getting set up to do this was already very expensive. And so that is speaker-1: Okay. speaker-0: you know, really why this ended up being so expensive, which gets passed on to the consumer, which ends up being less equitable. But again, you know, I think this the the the question is what is the time course here? This is a completely novel program, doing something that has never been done anywhere. And so, you know, I I hope the government can be supportive of continuing this program and doing so in a way that's cost effective. But I think also like America is not gonna just sort of like start rotating over to guided psilocybin services overnight. I mean, it is going to take time and you know, the newer the treatment, the more expensive it's going to be. So I I I kind of think with all of this, I mean, there are a lot of causes for concern. And I think, you know, we need to advocate where we can, but we also just need to be aware that this is going to be a slow process. Like it it's just Like it it's not going to be perfect right away, even in the best of circumstances, which we are certainly not facing now. But speaker-1: Yeah, I I like that perspective as well. Thinking about like the the all the researchers in the fifties and sixties. I mean, from their standpoint, they had put all this work in, done so many studies, and then they just got a kind of brick wall no. So I guess we are in a position where we don't have a brick wall no. There have been a few little brick walls here and there, but they're all small brick walls. Overall, it's still going. This is still the ship is still sailing. So even if it's sailing very slowly. There's something to be to remember to be grateful for about that, I guess. speaker-0: Yeah. speaker-1: So two so two final questions for you. One of them is a question that has been submitted by a podcast listener. ⁓ and the other one is from me personally. ⁓ the first one is somebody that has been listening to the podcast and submitted a question about anxiety. Okay. So this is a question ⁓ about phobias. So the the listener who wrote in with this question just wanted to know about how do phobias develop? Because this listener has two. A spider phobia and a belly button phobia, and they said that they just really don't understand it, why why there's so much fear of this tiny little spider or tiny little belly button and that they know it's so irrational, but they just have this total phobia. Can you can you shed some light on how these phobias might have developed? Spiders and belly buttons for this person. speaker-0: I don't I mean, I I don't know that much about specific phobias. I mean, I think there's sort of ⁓ they're probably one of the conditions, if not the condition where the you know, sort of a just a straight behaviorist model makes the most sense. Fear conditioning, which is essentially a Pavlovian response where, you know, you get conditioned to having a certain response and then every time you have the stimulus. you have that response again and it starts intensifying over time such that when you're exposed to the stimulus, eventually there's just this sort of instantaneous response. Right. And so then you need to extinguish the fear. I I've long wondered about like could psychedelics help with that? I I think certainly people are probably for the most part less susceptible to a fear response To the normal external stimuli that make them experience fear and anxiety in the acute psychedelic state. I think many people would would agree with that statement. ⁓ does that actually have any like longer term impact? I I don't know. It's a really good question. I mean, I I heard one story of somebody who did ketamine therapy who who told me a a story of of doing something with ketamine and fear extinction, actually of having somebody handle snakes. ⁓ while they were on ketamine, which I probably would not recommend anybody do in a in a practice setting, but this was a story that was told to me that it actually worked. So I'm just passing on a second hand story and I found it very interesting and and wondered about specific phobias and then probably forgot about it until being asked this question now. So it's a very interesting question. Maybe somebody will research it someday. Yeah. speaker-1: Thank you to whoever sent that one in for for ⁓ sparking a little fire under potential new research opportunity. ⁓ I think I have heard as well a story of somebody that had fear of flying. I'm pretty I can't remember where I heard this story before, but I'm pretty sure it was someone that was saying that that their psychedelic experiences helped them with a fear of flying. It would make sense from the kind of Rebus model. what's the neuroscientist's perspective on why a psychedelic might help us? speaker-0: I I'm I'm not so I I'm part of the Center for Neuroscience and Psychedelics, but I would I'm very far from being a neuroscientist myself, so I I would not want to sell myself on that. I mean I I From what yeah, I mean I I I I guess like the the Rebus model, what is it what would it do with the response to sp specific phobia is you have a sort of pre-programmed idea of a spider such that the moment your brain speaker-1: You're better than me though. speaker-0: visually perceive something that's shaped like a spider, it sort of triggers this whole set of, you know, priors, essentially, which is what psychedelics are disrupting. They're disrupting priors that you already have. ⁓ But does it lead to a to a permanent shift? I don't know. speaker-1: Maybe temporary and maybe the temporary shift is where you can do that extinction work because people with a really strong phobia is often doing that kind of ⁓ exposure therapy work is really intimidating, they just don't want to do it. But maybe it would give enough of a relaxation of those prior beliefs that actually the idea of doing some, I guess looking first at a picture of a spider and then, you know, moving up towards actually touching a spider. ⁓ so yeah, interesting to think about. Okay, final question. Yeah. This so in our email exchanges, you mentioned that you had been using the Pearl Dive with the IBS study. I don't know whether you used it with all the participants or but I would just love to hear some stories. I'd love some feedback. speaker-0: You know, it was useful because it was, you know, it was basically like I I think the most useful aspect of it is that gives people a brief non-drug-induced kind of dry run of what it's going to be like to close your eyes and put yourself in a vulnerable position, you know, before actually doing this, with the same people in the room who are going to be in the room when you do the medicine day. And so I think. Yeah, I mean, one person got very emotional. ⁓ I remember that. So, you know, I think these exercises that can, you know, very quickly bring people into a deep state. I don't know, it it it it's pretty amazing how quickly you can kind of change the energy in the room and and really kind of get somebody into an inner state. But some people were more easy easily kind of engaged with it than others, which is not surprising. That's just, you know, if you do a mindfulness exercise, some people are really gonna be able to drop in. And other people, you know, have a hard time with it. speaker-1: Mm. Yes. Yes. We're thinking of doing another one which would be more just like really grounding, grounding for when people are f for on the day of a journey, for on the day of a psychedelic session, because this one was obviously for preparation beforehand, like the day before or when whenever, the week before maybe, but thinking of something that would be like one of those journeys but ⁓ for people as they're about to go in, if they are super anxious. So something that's very, very grounding and very, very gentle would be based around trees, because most of the stuff we do now is based on trees. Just like the the feeling of like sinking into the moss of a forest floor. So I guess as the, you know, the clinical models become more and more, I suppose the the license the models that get licensed will probably be quite medical and clinical and quite kind of, I suppose, clean. ⁓ the more I'm interested in like these kind of tools that can be wraparound tools that people can kind of find themselves speaker-0: I guess what what I try to convey in a room, and this is true psychedelics or not, I mean my my main job, I work in the psychiatric emergency room, which is as you can imagine, fairly chaotic. And I just I just try to really exude a a calmness. Just being being able to bring that to the room as an offering is really important. Like just being like just like, you know, it's okay. Like like if people are anxious, like that's okay. speaker-1: You do have a very calm, steady, grounded presence. I'm really interested in where that comes from in you. Because I see that as part of connectedness. Like that's a deep connection to self and a connection to a faith in something like a trust, like a kind of existential trust that brings a sense of calm. Where does that come from in you? Where does it live in you? speaker-0: That's a question. I don't know. I mean, I've done a lot of holotropic breath work. I would say that that that's been that's been a huge part, honestly, of just my whole thing with psychedelics and just being able to just be open to, you know, anything that comes up and just sort of like leaning into trusting the process, no matter what. And of course, you know, the nice thing about breath work is I mean, people can have after effects, but you know. things really you know if you really do need to slow things down, you can. ⁓ but I but breath work has been specifically pretty significant for that and and the the folks that have taught me and trained me in that just kind of just like being okay. I mean people are having experiences. If people look, you know weeping or screaming or, you know, anything like it's it's okay. ⁓ but at the same time to absolutely, you know, be very attentive to everything that's going on and to care deeply about it. Not you know, it's not a cavalier attitude. It's not a ⁓ they're anxious, they'll be fine. I mean that there's there's plenty of that in the field and that's damaging. speaker-1: Yeah. ⁓ that's really good to hear that breath work had that impact on you. I'm also a huge fan. yeah, and it's nice to hear clinicians talk about it because I think it's an undersung hero of this work, actually holotropic breath work and other models as well. So Franklin King, thank you so much for your time and your work and being here with us and thanks to everyone for listening ⁓ to this episode of Stand in the Circle.